Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2019 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present Phase 2 Data for SEL-212 in Chronic Refractory Gout at Upcoming 2019 ACR Annual Meeting

WATERTOWN, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
October 23, 2019 10:48 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at 2019 ESGCT Annual Congress

Highlights the ability to prevent formation of vector-induced neutralizing antibodies (Nabs) and enable re-administration of AAV vectors in combination with Selecta’s ImmTOR (SVP-Rapamycin)...
September 25, 2019 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Participate in Two Investor Conferences in October

WATERTOWN, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
September 04, 2019 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Appoints Brad Dahms as Chief Financial Officer

WATERTOWN, Mass., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
September 03, 2019 08:07 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the Janney Healthcare Conference

WATERTOWN, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
August 08, 2019 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update

- New strategic partnership with gene therapy leader, AskBio, to jointly develop next-generation AAV-based gene therapies to address the unmet medical need for repeat dosing in patients with rare and...
August 07, 2019 07:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Combines ImmTOR™ Platform with AskBio’s Industry-Leading Gene Therapy Platform in Strategic Partnership

WATERTOWN, Mass. and RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced a...
August 01, 2019 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces Date of Second Quarter 2019 Financial Results Conference Call

WATERTOWN, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
July 31, 2019 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present at Canaccord Genuity’s 39th Annual Growth Conference on August 7, 2019

WATERTOWN, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
July 15, 2019 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Appoints Alison Schecter, M.D., as Chief Medical Officer

WATERTOWN, Mass., July 15, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right